Can Boston Scientific Outperform the Index in 2014?

Although it may seem unlikely at first glance, Boston Scientific (NYSE: BSX) could beat the wider index this year. Here's why.

Feb 21, 2014 at 6:07PM

The last five years have not been particularly happy ones for Boston Scientific (NYSE:BSX), or for its shareholders. Indeed, the medical devices manufacturer has delivered a profit (in terms of adjusted earnings per share) in only three of the last five years. However, cumulative losses in the other two years represent a significant majority of profit in the other three years, meaning total profit for the period (even on an adjusted basis) is pretty low.

Furthermore, the company's share price has not done all that much better, although at least it is higher than where it was five years ago. Still, share price gains of 61% are still some way off those of the S&P 500, which has posted capital gains of more than 150% during the same period.

But wait... growth at last
However, things seem to be looking up for shareholders in Boston Scientific! After an undoubtedly tough time, the company is forecast to grow EPS by 10% in 2014, and by as much as 20% in 2015. This is substantially above the average growth rate of the S&P 500 (which remains in the mid-single digits), and is comfortably better than anything the company has delivered in its recent past.

Excessive debt?
Furthermore, despite experiencing a challenging period, Boston Scientific remains financially sound. For instance, the company's debt-to-equity ratio is only moderately high at 65% (which means that for every $1 of net assets, Boston Scientific's balance sheet carries $0.65 of debt), and this shows just how conservative management has been with regards to how the business has been financed in recent years.

Indeed, it may have been tempting to take more risk and borrow a greater amount (especially with interest rates being so low), but Boston Scientific's balance sheet remains in surprisingly good health and ready to take advantage of the aforementioned above-average growth prospects that are forecast during the next two years.

Not a sector-wide problem
Of course, sector peers such as Abbott Laboratories (NYSE:ABT) and St Jude Medical (NYSE:STJ) appear to be in better shape that Boston Scientific. For instance, Abbott Laboratories has been profitable throughout the last five years, and is forecast to grow EPS by 9% in 2014, and by 12% in 2015 -- just shy of Boston Scientific's forecast growth rate.

Likewise, St Jude hasn't had the profitability issues of Boston Scientific; in other words, it has also made a profit in every year of the last five. It is also set to deliver EPS growth over the next two years. While EPS growth forecasts for St Jude are slightly below those of Abbott Laboratories and Boston Scientific (at 6% in 2014 and 8% in 2015), they remain above the S&P 500 average.

Performance not reflected In share prices
However, both St Jude and Abbott Laboratories have underperformed the S&P 500 during the last five years, with Abbott Laboratories gaining just 42%, and St Jude posting capital gains of 76% (S&P +150%). These numbers are either side of Boston Scientific's 61%, which highlights just how poorly all three stocks have performed during the last five years, but also how much potential they have to narrow this underperformance in the future.

Looking ahead
Indeed, all three stocks have bright prospects. However, Boston Scientific could prove to be the winner this year, since it's the company with the most room for improvement, and the biggest turnaround potential. As such, while all three stocks could beat the S&P 500 this year, Boston Scientific could be the one to watch, as well as a  great stock, through the rest of 2014.

The Motley Fool's top stock for 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report, "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Peter Stephens has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers